X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, the companies aim to to jointly identify and develop molecular glue degraders against multiple therapeutic targets by combining Proxygen's innovative platform technology with MSD’s world class research and development capabilities.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $2,550.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2023
Details:
Under the terms of the agreement, the companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage. Proxygen has successfully developed a highly versatile glue degrader discovery engine.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $554.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2022
Details:
Proxygen’s unique molecular glue degrader discovery platform complements Boehringer Ingelheim’s focus on proteolysis targeting chimeras (PROTACs) in the aim of degrading cancer drivers that were previously considered undruggable.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
